Compare UVSP & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | MGTX |
|---|---|---|
| Founded | 1876 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1994 | 2018 |
| Metric | UVSP | MGTX |
|---|---|---|
| Price | $41.41 | $11.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $36.67 | $24.57 |
| AVG Volume (30 Days) | 192.8K | ★ 737.7K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 21.32 | ★ 33.02 |
| EPS | ★ 1.78 | 1.30 |
| Revenue | ★ $328,056,000.00 | $81,391,000.00 |
| Revenue This Year | $11.65 | $141.38 |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | $23.51 | ★ $9.50 |
| Revenue Growth | 9.64 | ★ 144.57 |
| 52 Week Low | $28.04 | $6.62 |
| 52 Week High | $45.46 | $15.35 |
| Indicator | UVSP | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.99 |
| Support Level | N/A | $12.39 |
| Resistance Level | N/A | $15.33 |
| Average True Range (ATR) | 0.00 | 0.48 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 0.00 | 16.24 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.